HDFC MF and ADIA Lead ₹777 Crore Block Deal in Corona Remedies
A massive shift in the shareholding pattern of pharmaceutical player Corona Remedies Limited took place on June 17, 2026, as major institutional players executed a significant block deal. The transaction saw marquee names like HDFC Mutual Fund and the Abu Dhabi Investment Authority (ADIA) stepping in to absorb a massive stake offloaded by private investors.
The Mechanics of the ₹777 Crore Divestment
The block deal was primarily driven by Sepia Investments, which offloaded 43,28,943 shares of Corona Remedies. At a transaction price of ₹1,730 per share, Sepia’s stake amounted to approximately ₹748.9 crore. Adding to this divestment, a second seller, Anchor Partners, sold 1,61,861 shares at the same price, contributing an additional ₹28 crore to the deal.
In total, the two sellers successfully exited or reduced their positions by worth approximately ₹776.9 crore. The execution of such a large-scale transaction at a uniform price of ₹1,730 per share highlights the strong institutional appetite for the pharmaceutical company’s stock despite the large volume.
HDFC Mutual Fund Emerges as the Dominant Buyer
The buy side of the deal was equally impressive, featuring twelve distinct institutional investors. HDFC Mutual Fund emerged as the primary driver of the transaction, acquiring 24,50,000 shares. This purchase, valued at roughly ₹423.9 crore, accounted for more than half of the total deal value, signaling high confidence from India's leading asset manager.
Other significant domestic and international players included:
- Aditya Birla Sun Life Mutual Fund: Purchased 4,90,000 shares worth ₹84.8 crore.
- Invesco Mutual Fund: Acquired 2,89,017 shares valued at ₹50 crore.
- Kotak Mahindra Mutual Fund: Picked up 1,61,861 shares worth ₹28 crore, exactly matching the quantity sold by Anchor Partners.
- WhiteOak Capital Mutual Fund: Bought 1,45,000 shares for ₹25.1 crore.
Global Institutional Interest in Corona Remedies
The deal also showcased significant interest from international sovereign and asset management funds. The Abu Dhabi Investment Authority (ADIA) participated by purchasing 39,130 shares worth ₹6.8 crore.
International heavyweights also made their mark:
- Aberdeen Asset Management entities: Aberdeen Asian Smaller Companies Investment Trust Plc bought 4,50,868 shares (₹78 crore), while the Aberdeen Standard Sicav I fund picked up 2,74,132 shares (₹47.4 crore).
- WhiteOak and Ashoka Funds: India Acorn ICAV - Ashoka WhiteOak Emerging Markets Equity Fund invested ₹25.7 crore, while the Ashoka WhiteOak ex China fund added ₹5.1 crore to the buy side.
Smaller but notable participations came from Factory Mutual Insurance Company (₹1.9 crore) and the TCW White Oak Emerging Markets Equity Fund (₹33 lakh), rounding out a diverse pool of global capital entering the company.
Key Takeaways
- Major Exit: Sepia Investments and Anchor Partners offloaded a combined total of approximately ₹776.9 crore in Corona Remedies shares via a block deal.
- HDFC MF Dominance: HDFC Mutual Fund was the largest buyer, absorbing over ₹423 crore worth of shares, representing more than 50% of the total deal volume.
- Diverse Buyer Profile: The transaction saw a mix of domestic giants (Aditya Birla, Kotak, Invesco) and international institutions (ADIA, Aberdeen, WhiteOak), indicating broad-based institutional interest.